cancer
Nathalie Corvaïa, Chief Scientific Officer at MaaT Pharma, gives an overview of preclinical and clinical results for MaaT013 and MaaT033.
This partnership aims to leverage Microba's advanced technology platform for measuring the human gut microbiome to discover novel biomarkers for pancreatic cancer detection.
The findings of a recent study identified microbiota signatures that may allow clinicians to predict the outcomes of CAR-T immunotherapy.
Microbiomepost discussed with Lorella Tripodi, University Federico II of Naples, about the research she is working with her colleagues.
Numerous evidences demonstrate the involvement of the sex hormone-gut microbiome axis in regulating the antitumor efficacy of ICIs.
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology, which provides greater…
First and only FDA-approved orally administered microbiota-based therapeutic, validating Seres’ microbiome platform –
The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to…
The findings of a recent study suggest that tilimycin-producing bacteria can cause genetic mutations in the colon and increase a person’s susceptibility to disease.
The findings of a new study shed light on a general mechanism by which gut bacteria may influence anti-cancer immune responses.
